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INTRODUCTION
Gingival fibromatosis (GF) comprises a rare clinical condition
characterized by abnormally diffuse or localized growth of the
maxillary and mandibular gingiva. The condition among others
occurs as a side effect of some medications. It may be related to
hereditary factors or in some cases the aetiology of the enlargement
remains unknown (1-3). Hereditary gingival fibromatosis (HGF)
may manifest as an autosomal-dominant or, less commonly, an
autosomal-recessive mode of inheritance, either as an isolated
disorder or as part of a syndrome (2, 4-6). Autosomal dominant
forms of GF, which are usually non-syndromic, have been
genetically linked to the chromosomes 2p21-p22 and 5q13-q22.
Recently, a mutation in the Son-of-Sevenless (SOS-1) gene has
been suggested as a possible cause of isolated (non-syndromic)
gingival fibromatosis. SOS-1 is a guanine nucleotide-exchange
factor that functions in the transduction of signals that control cell
growth and differentiation. A single base insertion mutation (SOS-
1 g.126,142-126,143insC) introduces a frameshift, creating a
premature stop codon, abolishing 4 functionally important proline-
rich SH3 binding domains normally present in the carboxyl-
terminal region of the SOS-1 protein (7). The resultant protein
chimera has enhanced activity, since it lacks the carboxyl-terminal
domain that normally exerts negative allosteric control (8). This
mutation causes HGF in humans, and similar SOS-1 deletion
constructs are functional in animal models, and a transgenic mouse
construct with a comparable SOS-1 chimera produces a skin
hypertrophy phenotype (7, 9-11). A mutation in SOS-1 gene has
been associated with increased fibroblast proliferation and collagen
matrix synthesis in HGF (12).
Although the overgrown tissue does not cause a pain, it may
eventually cover most of the teeth. The condition may hinder
oral cavity hygiene and cause bone loss, result in speech
disturbance, difficulties with mastication, and, in extreme cases,
it may distort the jaws (11, 13, 14). A classic feature of GF is that
epithelial rete pegs extend deep into the connective tissue
compared with normal tissues, and contains fibrotic connective
tissue with various levels of inflammation (10, 15-18).
Although the mechanisms that trigger fibrosis in the course
of GF are extensively described, this topic is still not fully
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Gingival fibromatosis is a progressive enlargement of the gingiva. It may hinder oral cavity hygiene and result in
underlying bone loss. The long-term benefits of surgery cannot be predicted. On the other hand, alternative, efficient and
non-invasive methods are not available at present. The aim of this study was to test the inhibitory effects of a chimeric
IgG variant on collagen fibril formation in the cell culture of gingival fibroblasts taken from a patient with hereditary
gingival fibromatosis with a high propensity for recurrence. Gingival biopsies were collected from the mandibular
gingiva and used for histological evaluation as well as to establish a fibroblast culture. A histological evaluation was
made in haematoxylin-eosin and Heidenhain's trichrome stained tissue sections. The inhibitory effect of a chimeric
antibody on collagen fibril formation was determined in fibroblast cultures by using a collagen-specific Western blot and
immunofluorescent staining. A histological evaluation revealed epithelial acanthosis with singular elongated rete pegs
extending into the underlying connective tissue stroma that consisted of locally abundant, irregular collagen bundles.
Based on observations with an in vitro model we conclude that a chimeric anti-collagen antibody efficiently inhibits
collagen fibril accumulation in cell culture derived from diffuse, hereditary gingival fibromatosis that is characterized
by a high propensity for recurrence (high proliferation index). Employing cell cultures from standardized group of
patients with recurrent hereditary gingival fibromatosis as well as standarizing relevant 3D (tissue-like) models will be
crucial for further tests of the antibody.
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elucidated (19-22). The most attractive concept is that
molecular matrix remodeling programs are initiated in epithelial
cells that enable these now motile and transitioning cells to
invade through basement membranes and migrate into
connective tissue stroma where they contribute to new
extracellular matrix (ECM) production (21). Epithelial-to-
mesenchymal transition (EMT) is a process in which epithelial
cell-cell and cell-extracellular matrix interactions are weakened
as epithelial cells trans-differentiate into fibrogenic fibroblast-
like cells. Although a normal process in development, EMT
underlies pathological processes in mature tissues including
progression of tumors of epithelial origin, and heart, lung, liver,
and kidney fibrosis (20). Additionally, in this process are
involved several pro-fibrogenic cytokines and receptors, such
as connective tissue growth factor (CTGF) and transforming
growth factor b1 (TGFb1) which are considered the main
inducers of EMT (23, 24). GF is characterized by elevated
levels of pro-fibrogenic cytokines, including TGFb1 and CTGF.
Thus, another concept is that growth factors trigger fibrosis via
direct regulation of molecules involved in collagen and other
ECM components synthesis. At present, appropriate oral
hygiene and scaling are sufficient for localized and minimal
enlargements, while cases of massive gingival overgrowth
require surgical correction (25). On the other hand, the
inaccessibility of alternative, effective, and less invasive
methods indicates on the importance of discerning studies
testing novel tools that might become valuable to GF treatment
in the future.
Recently, it has been proposed that the extracellular process
of collagen fibril formation may serve as a valid target for
reducing collagen deposits in fibrotic tissues. It has been
demonstrated that employing a monoclonal antibody that targets
the C-terminal telopeptide of the a2 chain of collagen I blocks
critical collagen I-collagen I interaction, thereby reducing the
amount of collagen deposits in vitro and in models representing
growth of fibrotic tissues (26). Furthermore, recently Fertala et
al. shown efficient inhibition of collagen fibril formation in vivo
and in cultures of various cells associated with the fibrotic
process that develops after trauma by using a novel chimeric
antibody variant (chIgG) (27).
The objective of this study was testing in in vitro conditions
the inhibitory potential of a novel chimeric chIgG in a highly
recurrent diffuse hereditary gingival fibromatosis.
MATERIAL AND METHODS
The study was carried out in accordance with the
Declaration of Helsinki and the consent of the patient and
healthy subjects was obtained prior to the study as approved by
the Bioethical Committee of the Jagiellonian University,
Medical College in Cracow, Poland.
Gingival biopsies were collected from the anterior region of
the mandibular gingiva of the patient diagnosed with non-
syndromic, diffuse, hereditary gingival fibromatosis with a high
rate of lesion recurrence. The diagnosis was based on an
intraoral examination, the patient's medical/family history,
histological evaluation of the gingival biopsy and routine blood
tests. Twelve months earlier the patient had undergone surgery
with complete excision of the lesion. Gingival fibroblast cultures
established from three healthy subjects qualified to the
orthodontic treatment were used as controls in tests performed
with chimeric anti-collagen antibody. The chimeric antibody
variant (chIgG) tested in this study was constructed and kindly
provided by dr. A. Fertala from Department of Orthopaedic
Surgery, Jefferson Medical College, Thomas Jefferson
University, Philadelphia, PA, USA.
Histology of gingival biopsies from hereditary gingival
fibromatosis
Two gingival biopsies (1 × 2 mm, 2 × 2 mm) obtained from
the anterior region of the mandibular gingiva of HGF patient were
fixed in 10% formalin in a phosphate buffered saline (PBS) for 24
hours at 4°C. The tissue was dehydrated, paraffin embedded and
serially sectioned (thickness 7 µm). A histo-morphological
evaluation was conducted in gingival sections stained according to
the haematoxylin-eosin method and using a fluorescent
microscope (Nikon Eclipse Ti, Japan) connected to NIS-Elements
F 3.0 software (Nikon Inc.). Heidenhain's trichrome stain was
used to visualize collagen fibers in tissue sections.
Cell culture
Gingival biopsies from patient with hereditary gingival
fibromatosis and from controls were used to establish fibroblast
cultures. In brief, following the enzymatic separation of the
epithelial layer the remaining connective tissue was digested with
0.1% collagenase I (Invitrogen). After digestion, the cell pellet
was plated in T25 flask in Dulbecco's Modified Eagle Medium
(DMEM, PAA GmbH) supplemented with 10% heat-inactivated
foetal bovine serum (FBS, PAA), penicillin/streptomycin (50
u/ml), gentamicin (50 u/ml), and nystatin (10 µg/ml, PAA), at
37°C in a humidified atmosphere containing 5% CO2. The
homogeneity of the gingival fibroblast culture was confirmed
after passage 1 by immunofluorescent staining (vimentin+,
cytokeratin–). Gingival fibroblast cultures at passage 3–5 were
used for the experiments. Cell viability was confirmed by Trypan
blue staining and amounted to 97–99%.
Inhibition of collagen deposit formation in fibroblast cultures
in the presence of the anti-a2Ct chIgG.
Western blot
In brief, for Western blot assays, 50 × 103 cells per well were
seeded into a 24-well plate. Cell cultures were overlayed with a
fresh medium supplemented with 40 µg/ml of L-ascorbic acid
phosphate magnesium salt n-hydrate (Wako Pure Chemical Co.)
and a mixture of 70-kDa and 400-kDa Ficoll (Sigma-Aldrich)
added at concentrations of 40 mg/ml and 25 mg/ml, respectively.
Subsequently, chIgG was added to the medium at a concentration of
70 µg/ml. Cell cultures were maintained for 6 days and the medium
was changed every 2 days. The optimal concentration of chIgG for
cell culture utility and the cytotoxic assays were standardized
previously (27). Cell lysates were collected by employing a lysis
buffer consisting of 1% SDS, 1% sodium deoxycholate, 0.1%
Triton X-100, 10 mM EDTA, 3% b-mercaptoethanol and a mixture
of protease inhibitors (Thermo Scientific). The lysates (60 µg of
protein, a Bradford protein assay) were electrophoresed in
polyacrylamide gels followed by their transfer onto nitrocellulose
membranes. Collagen I was detected using a polyclonal anti-
collagen I antibody, as described previously (27). Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was detected with an anti-
GAPDH antibody (Santa Cruz Biotechnology Inc.).
Immunofluorescent staining
For the immunostaining assays, 15 × 103 cells per well were
seeded into an 8-chamber slide. Further procedures were
performed identical to the Western blot assays. The medium was
supplemented with chIgG (70 µg/ml). Cell cultures were
maintained for 6 days and the medium was changed every 2
days. The cells were fixed with ice-cold methanol, rinsed with
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PBS and then collagen fibrils were immunolocalized with the
primary polyclonal rabbit anti-collagen I antibodies, followed by
the secondary anti-rabbit IgG antibodies conjugated to Alexa
Fluor 594 (Invitrogen). The nuclei of the examined cells were
stained with 4',6-diamidino-2-phenylindole (DAPI). The
immunofluorescent reaction was analyzed with a fluorescent
microscope (Eclipse E600, Nikon Inc.). Microphotographs were
obtained with a digital camera (DS-Qi1Mc, Nikon Inc.)
controlled by the NIS-Elements software (Nikon Inc.).
RESULTS
Histological evaluation of gingival biopsies from patient with
hereditary gingival fibromatosis
A microscopic evaluation revealed epithelial acanthosis
with singular elongated or enlarged rete pegs extending into
underlying connective tissue stroma (Fig. 1A-1C). Locally
abundant, irregular collagen bundles were visualized within the
connective stroma using Heidenhain's trichrome stain (Fig.
1D-1F). Inflammatory cells were distributed throughout almost
the entire connective tissue (Fig. 1A-1C). Inflammatory
infiltrates were characterized by the prevalence of oval-shaped
cells with a round, eccentrically located nucleus and an
abundant basophilic cytoplasm. The nuclear chromatin of those
cells was coarse and distributed in a pattern sometimes
resembling the spokes of a wheel (cartwheel nucleus). The
other predominant cell population found was represented by
large mononuclear cells with a vesicular, elongated or kidney-
shaped nucleus with a clearly visible nuclear membrane as well
as an abundant, and eosinophilic cytoplasm. Two predominant
populations of cells that infiltrated the overgrown gingival
tissue were identified as plasmocytes and histiocytes,
respectively. The third and less numerous population was
represented by lymphocytes.
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Fig. 1. Histological presence of
hereditary gingival fibromatosis:
epithelium and lamina propria
visible in sections stained with
haematoxylin and eosin, original
magnification 100 × (A–C); collagen
fibrils stained with Heidenhain's
trichrome, magnification 100 ×
(D–F). Bars = 100 µm.
Fig. 2. Western blot assays of
collagen I extracted from primary
gingival fibroblast cultures derived
from a patient with recurrent,
diffuse, hereditary gingival
fibromatosis, A); and from controls,
B). Cells were cultured with the
inhibitory chIgG variant of the anti-
a2Ct antibody (A - left; B - middle);
cells cultured with hIgG (A - right; 
B - right) or in the absence of IgG 
(A - middle; B - left). Experiments
were repeated three times and
representative images of Western
blots are presented. Symbols:
inhibitory chimeric IgG, inhibitory
chIgG variant; human non-inhibitory
IgG, hIgG; No IgG, sample not
treated with any IgG variant;
Collagen I, partially processed pro-
a1 chains and cross-linked forms of
a1 chains; GAPDH, glyceraldehyde
3-phosphate dehydrogenase;
indicates uniform gel loading and
provides a reference for the a1
collagen chain.
The inhibitory effect of chimeric anti-a2Ct chIgG on collagen
fibril formation
Collagen fibril inhibition was measured using Western blot
and immunostaining assays. In the case of Western blot we used
cell lysates from fibroblast cultures maintained for 6 days in the
presence of therapeutic chIgG at a concentration of 70 µg/ml. As
shown in Fig. 2, chIgG almost completely blocked collagen fibril
formation, while the same effect was not observed after cells
were treated with a non-inhibitory hIgG or in the absence of IgG.
Microscopic analysis revealed relatively abundant collagen I
fibers in the presence of control hIgG (Fig. 3A). After treatment
with therapeutic chIgG fibril deposits had been reduced to almost
zero (Fig. 3B). Gingival fibroblast cultures established from
healthy subjects were used as controls (Fig. 3C-3D).
DISCUSSION
GF is a condition characterized by progressive enlargement of
the gingiva. A common feature of the condition is a problem with
maintaining oral hygiene, speech disturbances, and difficulties with
mastication (13, 14, 28). If left untreated, the enlarged tissue may
eventually cover most of the teeth and because of the difficulties in
maintaining oral hygiene, cause bone loss. The condition may also
induce caries development and other inflammatory periodontal
disorders (11, 13, 23). Additionally, oral infections stemming from
gingival overgrowth in patients with unbalanced normal
microbiota of oral cavity may lead to activation of Th17 cells and
macrophages which upon induction produce excessive levels of
proinflammatory cytokines. This process, in turn, can potentially
impair systemic health of the patients (29, 30). Epithelial
acanthosis with its potential cosmetic implications and tendency to
provide a niche for further growth of microorganism, the build-up
of plaque, and gingival inflammation, is still challenge for
periodontists to diagnose and manage effectively.
Hereditary gingival fibromatosis may be transmitted as a
Mendelian trait, and both autosomal dominant and autosomal
recessive transmission have been reported (31). Linkage studies
have localized loci for isolated nonsyndromic autosomal
dominant forms of gingival fibromatosis to chromosome 2p21-
p22 (32) and to chromosome 5q13-q22 (33). In addition to
nonsyndromic forms, GF has been associated with a variety of
syndromic manifestations. Hart et al. performed sequence
analysis of 6 known candidate genes, as well as 10 additional,
previously uncharacterized genes within the refined interval, and
identified a mutation in the SOS-1 gene, that segregated with the
HGF phenotype in a large group of members of a Brazilian
family (7). It has been suggested that the g.126,142-126,143insC
mutation produces the truncated protein chimera
p.K1084fsX1105 that causes HGF through a gain-of-function
mechanism. However, why the HGF phenotype appears
localized to the gingiva is unknown. The keratinized masticatory
mucosa is recognized to be developmentally unique, and
different tissue-specific signaling pathways in this unique tissue
may be responsible for the limited tissue distribution of the GF
phenotype. Although the sites-specific localization of this
phenotype is remarkable, the gingiva is also the only site
affected in drug-induced and most syndromic forms of GF. The
SOS-1 mutation in individuals with HGF described by Hart et al.
identified the first genetic mutation for isolated HGF (7).
Identification of the specific genetic basis in HGF should help to
elucidate the pathogenic mechanism by which gingival
overgrowth occurs (34). Otherwise, hereditary gingival
fibromatosis displays genetic heterogeneity, and mutations in
other genes are likely involved (35, 36). In turn, Lee et al. (12)
analyzed histological, morphological, and proliferation
characteristics in monolayer and three-dimensional cultures of
fibroblasts with the SOS-1 g.126,142-126,143insC mutation.
Histological assessment of HGF gingiva indicated increased
numbers of fibroblasts (30%) and increased collagen (10%). Cell
proliferation studies demonstrated increased growth rates and 5-
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Fig. 3. Microscopic assays of
collagen fibrils deposited in
fibroblast cultures derived
from a patient diagnosed with
recurrent, diffuse, hereditary
gingival fibromatosis (A-B),
or in fibroblast cultures from
controls (C-D). Cells were
cultured in the presence of
non-inhibitory hIgG, (A, C) or
with the inhibitory chIgG
variant of the anti-a2Ct
antibody (B, D). Experiments
were performed three times,
and representative images are
presented. Magnification 
200 ×. Bars = 100 µm.
bromo-2-deoxyuridine incorporation for HGF fibroblasts. Flow
cytometry showed greater proportions of HGF fibroblasts in the
G2/M phase. Subsequently, HGF derived fibroblasts in three-
dimensional culture showed greater cell proliferation, higher cell
density, and alteration of surrounding collagen matrix. The
observations from this study clearly shown that increased
fibroblast numbers and collagen matrix changes are associated
with mutation of the SOS-1 gene in vitro and in vivo (12).
Increased fibroblasts proliferation and extracellular matrix
deposition in HGF was also reported by others (16, 17, 37-40).
Recently, it has been proposed that the extracellular process
of collagen fibril formation may serve as a valid target for
reducing the mass of collagen-rich fibrotic tissues. It has been
postulated that targeting the specific process of fibril formation
may offer not only an effective but also a safe way to reduce
collagen synthesis in fibrotic tissues. Since fibril formation is
driven by telopeptide mediated collagen-collagen interaction, an
anti-a2Ct antibody was generated that specifically binds to the
telopeptide of the a2 chain of human collagen I, thereby
blocking its critical binding interaction (26, 41). Consequently,
the anti-a2Ct antibody was tested as the inhibitor of localized
fibrosis in a keloid-like model and these initial tests indicated the
great potential of the anti-a2Ct antibody to reduce the mass of
the formed fibrotic tissue (26). However, the prototypic anti-
a2Ct antibody originates from mice and it belongs to the IgA
class. As a consequence, its utility as a therapeutic agent in
human patients is limited. Subsequently, the same group
engineered a chimeric antibody variant (chIgG), consisting of
variable domains derived from the prototypic IgA-type anti-
a2Ct antibody and the constant domains of the human IgG
(hIgG). The novel antibody was tested for its ability to inhibit
collagen fibril formation in vivo and in cultures of various cells
associated with the fibrotic process that develops in response to
trauma (27). According to above evidences we proposed herein
to study a novel approach to treating gingival overgrowth lesions
using a novel chimeric IgG. To test the inhibitory potential of a
novel anti-collagen IgG we used gingival fibroblasts from a
patient diagnosed with diffuse, hereditary non-syndromic
gingival fibromatosis with the recurrence of about 12 months
after complete excision of the lesion. Histological evaluation of
gingival sections revealed epithelial acanthosis with singular
elongated or enlarged rete pegs extending into the underlying
connective tissue stroma. Abundant, irregular collagen bundles
were found locally in the stromal part of the gingiva. We
observed an approximately 2.7-fold increase in the expression of
procollagen I and a roughly 2-fold increase in proliferation at 72
hours in fibroblast cultures derived from this patient as
compared to controls (data not shown). The tests conducted in
the present study shown almost complete inhibition of collagen
fibril formation, and this effect was not detected in cells
supplemented with non-inhibitory hIgG or in the absence of IgG
(Fig. 2). This observation was confirmed by immunofluorescent
microscopic analysis of cell cultures treated with non-inhibitory
hIgG (Fig. 3A), or therapeutic chIgG, respectively (Fig. 3B).
As shown by others a mutation in SOS-1 gene has been
associated with increased fibroblasts proliferation and collagen
matrix synthesis in HGF (12). Increased proliferation was also
noted in fibroblasts used in the current study that were isolated
from hereditary gingival overgrowth (unpublished data).
Therefore another attempt to counteract gingival overgrowth is
employment of chemicals that inhibit gingival cells (fibroblasts)
proliferation. An attractive example is a chemotherapeutic agent
mitoxantrone (MTX) that was tested using dental pulp stem cells
(DPSCs) and human dermal fibroblasts (HDFs) (42). MTX is
successfully used in clinical medicine, e.g. it limits the
frequency of relapse and is effective in slowing the progression
of several variants of multiple sclerosis (MS) (43). MTX
mechanisms of action involve DNA intercalation through
hydrogen bonding as well as inhibition of topoisomerase II
which induces double strand breaks (DSBs) of DNA (44). It has
been shown that treatment of DPSCs and HDFs with clinical
concentrations of MTX resulted in stress-induced premature
senescence (SIPS) that is a permanent cell cycle arrest in
response to DSBs observed in some cell types. It was also found
that lower concentration of MTX induced SIPS, while higher
concentration of MTX induced programmed cell death, which
was accompanied by increased expression of proapoptotic
protein puma and activation of effector caspases 3/7 in both cell
types. The results presented by Seifrtova et al. are interesting
and such approach would seem promising also with respect to
counteract gingival overgrowth. However, first, relevant studies
are needed that would clarify the effect of MTX on gingival
fibroblasts derived from HGF lesions, cells susceptibility and
response to this drug as well as its mechanisms of action.
Another interesting approach concerns employment of bone
marrow mesenchymal stem cells (BMSCs) and/or mesenchymal
stem cells (MSCs) of oral origin to therapy of a number of
periodontal diseases. DPSCs and periodontal ligament stem cells
(PDLSCs) are of particular interest. An abundant source of both
cell types are teeth (45, 46) and MSCs are normally obtained
from teeth removed during routine dental care. It has been
shown that DPSCs and PDLSCs induced apoptosis of some cells
in in vitro conditions (47, 48). Moreover, transplanted BMSCs in
response to appropriate pharmacological induction differentiated
into cementoblasts, osteoblasts, osteocytes and fibroblasts of the
regenerated tissue. Therefore replacement of abnormal
fibroblasts from overgrown gingival tissue by allogeneic and/or
autologous drafts of fibroblasts of MSCs origin, by DPSCs or
PDLSCs would be of some importance in supporting therapy
(regenerative phase) of gingival overgrowth lesions. Although
MSCs from dental sources such as the dental pulp, the
periodontal ligament and the gingiva represent a high potential
for tissue regeneration, its biology and "behaviour" within
regenerating tissues is yet not fully explored, indicating the need
for more research to speed the path to clinical applications.
Histological evaluation of gingival sections in the current
study revealed infiltrates of immune cells throughout almost the
entire connective tissue i.e. subepithelial connective tissue,
around vessels and capillaries, and within the connective stroma.
Epithelial acanthosis that lead to partial or complete coverage of
teeth provides a niche for microorganisms growth and the build-
up of plaque and gingival inflammation. If left untreated such a
condition may induce inflammatory diseases of the
periodontium. The risk of gingival inflammation is higher in
patients with unbalanced composition of normal oral microbiota,
e.g. lower amount of Lactobacilli spp. and decreased production
of H2O2 that negatively correlates with activation of Th17 cells,
and increased levels of IL-17 as well as TNFa (29). Activation
of Th17 cells and macrophages leading to excessive production
of proinflammatory cytokines and receptor activator of nuclear
factor kappa B ligand (RANKL) may cause activation of
osteoclasts resulting in bone loss (30). In turn, the interaction
between inflamed gingiva, dental plaque and the host response
to it may affect fibrotic process in the gingiva.
In conclusion, at present, an effective management of patients
with gingival fibromatosis clearly requires the active
involvement of both dental and medical professionals to
minimize the possibility of complications. Since the pathogenesis
of gingival enlargement is not well-understood treatment is still
largely limited to maintaining an improved level of oral hygiene,
professional scaling, root planning and the surgical excision of
overgrown tissue (24, 49). Non-surgical treatment is a far less
invasive technique than surgical approaches and it is considered
to be the first treatment option for GF. However, such a mode is
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insufficient in a relatively prevalent group of patients with diffuse
and/or recurrent gingival overgrowth. The long-term benefits of
surgery, particularly in the case of these patients, cannot be
predicted and they are exposed to the risk of consecutive surgical
procedures within relatively short time intervals, which may
affect the quality of a patient's life. It has been shown that
conventional gingivectomy with laser excision resulted in a better
treatment outcome with a reduced rate of recurrence when
compared to conventional gingivectomy with flap surgery (50).
Although this mode of treatment seems to be more effective than
routine surgery, the method still remains highly invasive for the
patient. Therefore, since the sole mode of treatment of GF
consists of invasive, surgical methods and the long-term benefit
of surgery in a number of patients cannot be predicted, discerning
studies testing novel tools that might be of value in the future
(alternative or supporting) treatment of gingival overgrowth are
of great importance. Finally, we report in the present study that
the chimeric IgG variant appears to be an effective tool in
counteracting collagen fibril accumulation in a fibroblast model
derived from diffuse, hereditary gingival fibromatosis. Notably, a
novel anti-collagen IgG was effective in culture of cells that
derive from gingival lesion with a high propensity to recurrence
(high proliferation index). Employing cell cultures from
standardized group of patients with recurrent HGF as well as
standardising relevant 3D (tissue-like) models will be crucial for
further tests of the antibody.
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